#1 Clinical Trials Search in Europe

Izaflortaucipir (18F)

Izaflortaucipir (18F), also known as [18F]PI-2620, is an innovative radiotracer being studied in clinical trials for its potential to detect tau protein aggregates in the brain. This article explores how this compound is being used to investigate tau pathology in various neurodegenerative conditions, including Alzheimer’s disease, Down syndrome, and progressive supranuclear palsy. By enabling visualization of tau deposits through PET imaging, Izaflortaucipir (18F) may provide valuable insights into disease progression and aid in diagnosis and treatment monitoring.

Table of Contents

What is IZAFLORTAUCIPIR (18F)?

IZAFLORTAUCIPIR (18F), also known as 18F-PI-2620 or [18F]PI-2620, is an investigational radioactive tracer used in Positron Emission Tomography (PET) brain imaging[1]. It is being studied as a tool to detect and measure tau protein buildup in the brain, which is associated with certain neurodegenerative diseases[2].

How It Works

IZAFLORTAUCIPIR (18F) works by binding to abnormal tau protein deposits in the brain. When injected into a patient, it travels to the brain and attaches to areas where tau has accumulated. The radioactive tracer can then be detected by a PET scanner, creating detailed 3D images that show the location and amount of tau in the brain[3].

Conditions Being Studied

Researchers are investigating the use of IZAFLORTAUCIPIR (18F) in several neurodegenerative conditions, including:

  • Alzheimer’s Disease (AD): Both in the general population and in individuals with Down Syndrome, who are at higher risk for developing AD[3]
  • Progressive Supranuclear Palsy (PSP): A rare brain disorder that affects movement, balance, and eye control[2]
  • Frontotemporal Dementia: A group of brain disorders that primarily affect the frontal and temporal lobes of the brain[4]
  • Corticobasal Degeneration: A rare neurological disease that can cause movement difficulties and cognitive problems[4]

How It’s Administered

IZAFLORTAUCIPIR (18F) is given as an intravenous injection, typically as a slow bolus. The dose is usually around 185 MBq (megabecquerels), which is a measure of radioactivity[5]. After injection, patients undergo a PET scan, which can last up to 90 minutes[6].

Safety Information

As IZAFLORTAUCIPIR (18F) is still being studied, its full safety profile is not yet established. However, clinical trials are monitoring for potential side effects and adverse reactions. Common exclusion criteria for studies include:

  • Pregnancy or breastfeeding
  • Severe allergies or previous severe reactions to medications
  • Certain medical conditions that could interfere with the study results
  • Recent participation in other clinical trials

Patients should always discuss potential risks and benefits with their healthcare provider[5].

Ongoing Research

Several clinical trials are currently underway to evaluate IZAFLORTAUCIPIR (18F). These studies aim to:

  • Assess its effectiveness in detecting tau pathology in different neurodegenerative diseases
  • Compare it to other tau PET tracers
  • Evaluate its use in monitoring disease progression over time
  • Investigate its potential as a biomarker for early diagnosis and treatment monitoring[4]

Potential Benefits

If proven effective, IZAFLORTAUCIPIR (18F) could offer several benefits:

  • Earlier and more accurate diagnosis of tau-related neurodegenerative diseases
  • Improved monitoring of disease progression
  • Better evaluation of potential treatments targeting tau protein
  • Enhanced understanding of the role of tau in various brain disorders
  • Potential use as a tool in clinical trials for new therapies[6]

It’s important to note that while IZAFLORTAUCIPIR (18F) shows promise, it is still considered an investigational tool. More research is needed to fully understand its capabilities and limitations in diagnosing and monitoring neurodegenerative diseases.

Aspect Details
Drug Name Izaflortaucipir (18F), also known as [18F]PI-2620
Purpose Detection and quantification of tau protein aggregates in the brain
Administration Intravenous injection, typically 185 MBq
Imaging Technique Positron Emission Tomography (PET)
Primary Outcome Measure Standardized Uptake Value Ratio (SUVR)
Conditions Studied Alzheimer’s disease, Down syndrome, Progressive supranuclear palsy, other tauopathies
Key Applications Disease diagnosis, progression monitoring, treatment efficacy assessment
Safety Profile Generally well-tolerated, ongoing evaluation in clinical trials

FAQ

  • What is Izaflortaucipir (18F) and how does it work? Izaflortaucipir (18F), also known as [18F]PI-2620, is a radiotracer used in PET imaging. It binds to tau protein aggregates in the brain, allowing researchers to visualize and measure tau pathology associated with neurodegenerative diseases.
  • Which conditions are being studied using Izaflortaucipir (18F)? Clinical trials are investigating Izaflortaucipir (18F) in various conditions, including Alzheimer's disease, Down syndrome, progressive supranuclear palsy, and other neurodegenerative disorders characterized by tau protein accumulation.
  • How is Izaflortaucipir (18F) administered in clinical trials? Izaflortaucipir (18F) is typically administered as an intravenous injection. The dose used in most trials is around 185 MBq (megabecquerels), given as a single slow bolus injection.
  • What is the primary outcome measured in these clinical trials? The main outcome measured is usually the Standardized Uptake Value Ratio (SUVR) from PET images generated with Izaflortaucipir (18F). This ratio quantifies the amount of tau protein aggregates in different brain regions compared to a reference region, often the cerebellum.
  • Are there any safety concerns with using Izaflortaucipir (18F)? While safety is being evaluated in ongoing trials, Izaflortaucipir (18F) is generally well-tolerated. As with any radiopharmaceutical, there are considerations regarding radiation exposure. Participants are monitored for adverse effects, typically for 24 hours following administration.

Ongoing Clinical Trials on Izaflortaucipir (18F)

  • Study on the Use of 18F-PI-2620 to Detect Alzheimer’s in People with Down Syndrome

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Comparison of Three PET Tau Tracers ([18F]RO948, [18F]PI2620, and [18F]MK-6240) in People with Cognitive Impairment

    Recruiting

    2 1 1 1
    Investigated drugs:
    Spain

  • Study on the Use of 18F-PI-2620 for Patients with Progressive Supranuclear Palsy and Parkinson’s Disease

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Sleep and Temperature Changes in Alzheimer’s Disease for Down Syndrome Patients Using Izaflortaucipir (18F)

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effects of ACI-24.060 for Patients with Early Alzheimer’s Disease and Adults with Down Syndrome

    Recruiting

    1 1 1
    Investigated drugs:
    Spain

  • Study on Brain Imaging with [18F]PI-2620 for Progressive Supranuclear Palsy Patients

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Tau protein: A protein found in neurons that can form abnormal aggregates in certain neurodegenerative diseases, contributing to brain cell dysfunction and death.
  • PET (Positron Emission Tomography): An imaging technique that uses radioactive tracers to visualize and measure metabolic processes in the body, often used to study brain function and detect abnormalities.
  • Radiotracer: A radioactive compound used in medical imaging to highlight specific tissues or processes in the body.
  • SUVR (Standardized Uptake Value Ratio): A measure used in PET imaging to quantify the concentration of a radiotracer in a specific region compared to a reference region.
  • Alzheimer's disease: A progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks, characterized by the accumulation of abnormal proteins in the brain.
  • Down syndrome: A genetic disorder caused by the presence of an extra copy of chromosome 21, associated with intellectual disability and increased risk of early-onset Alzheimer's disease.
  • Progressive supranuclear palsy (PSP): A rare brain disorder that causes problems with movement, balance, speech, swallowing, vision, mood, behavior, and thinking.
  • Amyloid: Abnormal protein deposits that can accumulate in the brain and are associated with various neurodegenerative diseases.
  • Biomarker: A measurable indicator of a biological state or condition, often used to track disease progression or treatment effectiveness.
  • Cerebrospinal fluid (CSF): A clear, colorless fluid that surrounds the brain and spinal cord, often analyzed for biomarkers of neurological diseases.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aci-24-060-for-patients-with-early-alzheimers-disease-and-adults-with-down-syndrome/
  2. http://clinicaltrials.eu/trial-id/2023-503538-37-00
  3. http://clinicaltrials.eu/trial/study-on-sleep-and-temperature-changes-in-alzheimers-disease-for-down-syndrome-patients-using-izaflortaucipir-18f/
  4. http://clinicaltrials.eu/trial-id/2023-510508-31-01
  5. http://clinicaltrials.eu/trial-id/2023-508718-40-00
  6. http://clinicaltrials.eu/trial-id/2024-515574-27-00